Oruka Therapeutics (NASDAQ:ORKA) Reaches New 12-Month High – What’s Next?

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s stock price reached a new 52-week high on Monday . The stock traded as high as $54.00 and last traded at $57.68, with a volume of 17361 shares traded. The stock had previously closed at $53.31.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ORKA shares. UBS Group assumed coverage on shares of Oruka Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 price objective for the company. Piper Sandler began coverage on Oruka Therapeutics in a research report on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Guggenheim reiterated a “buy” rating and set a $60.00 price objective on shares of Oruka Therapeutics in a research report on Friday, March 13th. Finally, Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 16th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oruka Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $59.60.

Oruka Therapeutics Trading Up 7.8%

The business has a fifty day moving average price of $36.96 and a two-hundred day moving average price of $30.74. The firm has a market capitalization of $2.85 billion, a PE ratio of -31.07 and a beta of -0.54.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.16. On average, equities analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,641 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $40.91, for a total value of $312,593.31. Following the completion of the transaction, the insider owned 33,377 shares of the company’s stock, valued at $1,365,453.07. This trade represents a 18.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the sale, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 23,765 shares of company stock worth $849,575. 24.69% of the stock is owned by insiders.

Institutional Trading of Oruka Therapeutics

A number of large investors have recently made changes to their positions in the company. Royal Bank of Canada lifted its stake in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in Oruka Therapeutics by 0.9% during the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after acquiring an additional 420 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Oruka Therapeutics by 35.0% in the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after purchasing an additional 788 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Oruka Therapeutics by 62.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after purchasing an additional 904 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at $37,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.